G-quadruplexes in MTOR and induction of autophagy

Majumder, Piyali; Shukla, Chinmayee; Arya, Arjun; Sharma, Shubham; Datta, Bhaskar

doi:10.1038/s41598-024-52561-y

Cited by 2 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As anticipated, the possibility of targeting cancer cells through the pharmacological stabilization of naturally occurring G4 structures has long been considered by chemists, physicists, biologists, and clinicians as an opportunity for developing molecules that are able to selectively counteract tumor formation and progression. In agreement with this, the number of G4 ligands has significantly grown over the last 25 years, constituting a superfamily of molecules, with up to 3000 different members to date, distinguished for their structure and biological activity (see Figure 3 for notable examples reported in the text) [ 21 , 23 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 ].…”

Section: Limitations Of G4-based Antitumoral Therapiesmentioning

confidence: 84%

“…At the functional level, the alteration of VEGF-R promotes an impairment of vascularization and, consequently, an inhibition of tumor growth and dissemination. Again, a recent study published by Majumder and colleagues demonstrated the capability of TMPyP4 to impair the expression of mTOR, a key factor in the autophagic process [ 23 ].…”

Section: Therapeutic Relevance Of G4 Structures In Cancermentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Use of G4-Ligands in Cancer: State-of-the-Art and Future Perspectives

Iachettini,

Biroccio,

Zizza

2024

Pharmaceuticals

View full text Add to dashboard Cite

G-quadruplexes (G4s) are guanine-rich non-canonical secondary structures of nucleic acids that were identified in vitro almost half a century ago. Starting from the early 1980s, these structures were also observed in eukaryotic cells, first at the telomeric level and later in regulatory regions of cancer-related genes, in regulatory RNAs and within specific cell compartments such as lysosomes, mitochondria, and ribosomes. Because of the involvement of these structures in a large number of biological processes and in the pathogenesis of several diseases, including cancer, the interest in G4 targeting has exponentially increased in the last few years, and a great number of novel G4 ligands have been developed. Notably, G4 ligands represent a large family of heterogeneous molecules that can exert their functions by recognizing, binding, and stabilizing G4 structures in multiple ways. Regarding anti-cancer activity, the efficacy of G4 ligands was originally attributed to the capability of these molecules to inhibit the activity of telomerase, an enzyme that elongates telomeres and promotes endless replication in cancer cells. Thereafter, novel mechanisms through which G4 ligands exert their antitumoral activities have been defined, including the induction of DNA damage, control of gene expression, and regulation of metabolic pathways, among others. Here, we provided a perspective on the structure and function of G4 ligands with particular emphasis on their potential role as antitumoral agents. In particular, we critically examined the problems associated with the clinical translation of these molecules, trying to highlight the main aspects that should be taken into account during the phases of drug design and development. Indeed, taking advantage of the successes and failures, and the more recent technological progresses in the field, it would be possible to hypothesize the development of these molecules in the future that would represent a valid option for those cancers still missing effective therapies.

show abstract

Section: Limitations Of G4-based Antitumoral Therapiesmentioning

confidence: 84%

Section: Therapeutic Relevance Of G4 Structures In Cancermentioning

confidence: 99%

Therapeutic Use of G4-Ligands in Cancer: State-of-the-Art and Future Perspectives

Iachettini,

Biroccio,

Zizza

2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

The shaping of mRNA translation plasticity by RNA G-quadruplexes in cancer progression and therapy resistance

Cammas,

Desprairies,

Dassi

et al. 2024

NAR Cancer

View full text Add to dashboard Cite

Translational reprogramming in response to oncogenic signaling or microenvironmental stress factors shapes the proteome of cancer cells, enabling adaptation and phenotypic changes underlying cell plasticity, tumor progression and response to cancer therapy. Among the mechanisms regulating translation are RNA G-quadruplexes (RG4s), non-canonical four-stranded structures whose conformational modulation by small molecule ligands and RNA-binding proteins affects the expression of cancer proteins. Here, we discuss the role of RG4s in the regulation of mRNA translation by focusing on paradigmatic examples showing their contribution to adaptive mechanisms of mRNA translation in cancer.

show abstract

G-quadruplexes in MTOR and induction of autophagy

Cited by 2 publications

References 56 publications

Therapeutic Use of G4-Ligands in Cancer: State-of-the-Art and Future Perspectives

Therapeutic Use of G4-Ligands in Cancer: State-of-the-Art and Future Perspectives

The shaping of mRNA translation plasticity by RNA G-quadruplexes in cancer progression and therapy resistance

Contact Info

Product

Resources

About